Home Healthcare Medical Devices Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market

Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Last Updated: September 21, 2026 | Author: Debashree Bora | Format:

Asia-Pacific Cardiac Resynchronization Therapy (crt) Market Size

The Asia-Pacific Cardiac Resynchronization Therapy Market size was valued at USD 1.05 billion in 2025 and is projected to grow from USD 1.12 billion in 2026 to reach USD 1.88 billion by 2034, growing at a CAGR of 6.71% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Market Key Takeaways

Global Market Size & Growth

CRT-D dominates the market by Product.
Hospitals dominate the market by End-User.
Japan dominates the market by Country.
Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis

By Product

The Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market is segmented into CRT-Defibrillator and CRT-Pacemaker. CRT-Defibrillators combine cardiac resynchronization therapy with implantable cardioverter-defibrillator functionality, enabling ventricular synchronization while providing protection against potentially life-threatening ventricular arrhythmias. CRT-Pacemakers are primarily designed to improve ventricular coordination and cardiac function in eligible patients with heart failure and conduction abnormalities. Both products are used in advanced cardiac rhythm management, with product selection depending on patient condition, arrhythmia risk, clinical assessment, and treatment requirements. CRT-Pacemakers represent an important product category due to the growing need for cardiac resynchronization among patients with heart failure and conduction disorders across the region.

Increasing prevalence of cardiovascular diseases, rising incidence of heart failure, aging populations, improving access to advanced cardiac care, and technological advancements in implantable cardiac devices are supporting demand for both product categories. CRT-Defibrillators benefit from their combined resynchronization and defibrillation capabilities, while CRT-Pacemakers are supported by increasing diagnosis and management of heart failure and cardiac conduction abnormalities. Improvements in device miniaturization, battery performance, lead technology, remote monitoring, and implantation techniques are expected to strengthen adoption of advanced CRT systems across Asia-Pacific.

Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

By End User

The Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other End Users. Hospitals represent a major end-user segment because CRT implantation requires specialized cardiovascular infrastructure, diagnostic equipment, trained specialists, and post-procedure monitoring. Cardiac centers provide specialized services for cardiovascular diagnosis, device implantation, rhythm management, and long-term patient follow-up, while ambulatory surgical centers are becoming relevant for selected procedures that can be performed in outpatient settings. Other end users include specialized healthcare facilities and medical institutions involved in cardiac rhythm management and cardiovascular care.

Growing demand for advanced cardiac treatment, increasing prevalence of heart failure and rhythm disorders, expansion of specialized cardiac facilities, and improvements in minimally invasive implantation techniques are supporting demand across end-user settings. Hospitals continue to benefit from their comprehensive cardiovascular infrastructure, while cardiac centers are gaining importance because of their specialized expertise and increasing focus on advanced rhythm-management procedures. Ambulatory surgical centers can benefit from the expansion of outpatient cardiac interventions, while remote monitoring and improved follow-up technologies are enhancing long-term management of CRT patients. Increasing healthcare expenditure and improving access to specialized cardiovascular care are expected to further support CRT adoption across Asia-Pacific.

Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

List of Key and Emerging Players in Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market

Abbott
Boston Scientific Corporation
Medtronic
Biotronik SE & Co. Kg
Microport Scientific Corporation
LivaNova PLC
Medico S.R.L.

Key Industry Developments

May 2026 – Medtronic expanded the availability of its next-generation Cardiac Resynchronization Therapy Defibrillator (CRT-D) systems across Asia-Pacific, incorporating advanced conduction system pacing and AI-enabled diagnostics to improve heart failure management.
March 2026 – Abbott enhanced its cardiac rhythm management portfolio in Asia-Pacific by introducing upgraded CRT devices with remote monitoring capabilities and improved battery longevity, supporting better long-term outcomes for heart failure patients.
November 2025 – Boston Scientific received expanded regulatory approvals across Asia-Pacific for its Resonate™ and Momentum™ CRT-D systems, strengthening its presence in the region's rapidly growing cardiac rhythm management market.
July 2025 – BIOTRONIK expanded its cardiac implant portfolio by introducing advanced MRI-compatible CRT devices with enhanced remote monitoring features, enabling physicians across Asia-Pacific to optimize treatment for patients with heart failure and arrhythmias.

Report Scope

Segmentation

By Product 2
  • CRT-Defibrillator
  • CRT-Pacemaker
By End User 4
  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers
  • Other End Users
Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Biotronik SE & Co. Kg · Microport Scientific Corporation
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The Asia-Pacific cardiac resynchronization therapy market size was valued at USD 1.12 billion in 2026.

Key verticals adopting the Asia-Pacific cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE & Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.

Increasing geriatric population is the key driver for the growth of the Asia-Pacific cardiac resynchronization therapy market.

Government initiatives is one of the upcoming key trends in the Asia-Pacific cardiac resynchronization therapy market.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: